未知生产厂商
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose. Other features of this vaccine include potential activity with oral administration via a swish-and-swallow protocol. Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose. Other features of this vaccine include potential activity with oral administration via a swish-and-swallow protocol. Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
